These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA; Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721 [TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589 [TBL] [Abstract][Full Text] [Related]
9. Risk of thrombosis with lenalidomide and its prevention with aspirin. Hirsh J Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586 [TBL] [Abstract][Full Text] [Related]
10. Thrombotic complications of myeloma therapy. Zonder JA Hematology Am Soc Hematol Educ Program; 2006; ():348-55. PubMed ID: 17124082 [TBL] [Abstract][Full Text] [Related]
11. [Thromboprophylaxis in patients with multiply myeloma who receives chemotherapy with thalidomide]. Novosad OI; Kriachok IA; Kadnikova TV; Filonenko KS; Tytorenko IB; Martynchyk AV; Aleksyk OM; Gusachenko IuO; Filonenko IA Lik Sprava; 2011; (3-4):44-50. PubMed ID: 22416363 [TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147 [No Abstract] [Full Text] [Related]
15. Novel agents in myeloma: an exciting saga. Mark T; Niesvizky R; Coleman M Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986 [No Abstract] [Full Text] [Related]
16. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. Al-Ani F; Bermejo JM; Mateos MV; Louzada M Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753 [TBL] [Abstract][Full Text] [Related]
17. Anticoagulation regimens for thalidomide and lenalidomide. Zangari M Clin Adv Hematol Oncol; 2006 Sep; 4(9):658-9. PubMed ID: 17099621 [No Abstract] [Full Text] [Related]
18. Lenalidomide plus dexamethasone in multiple myeloma. Das M Lancet Oncol; 2018 Jan; 19(1):e12. PubMed ID: 29175148 [No Abstract] [Full Text] [Related]
19. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
20. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. Rus C; Bazzan M; Palumbo A; Bringhen S; Boccadoro M J Thromb Haemost; 2004 Nov; 2(11):2063-5. PubMed ID: 15550053 [No Abstract] [Full Text] [Related] [Next] [New Search]